Return to homepagePandemic Pact

SUPPLEMENTAL WORK - SARS-COV-2 PRECLINICAL WORK

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 272201700011C-P00011-9999-2

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020.0
    2021.0

  • Known Financial Commitments (USD)

    $1,500,152

  • Funder

    National Institutes of Health (NIH)

  • Principal Investigator

    . LAURIE SOWER

  • Research Location

    United States of America

  • Lead Research Institution

    CHRYSALIS BIOTHERAPEUTICS, INC.

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Chrysalis proposes to repurpose their regenerative drug, TP508, to treat COVID-19, due to its ability to reduce effects of acute lung injury, prevent normal tissue damage and reduce inflammation. TP508 has an existing efficacy profile in tissue regeneration clinical trials, an extensive safety profile (600 human subjects with no adverse effects), and is GMP manufactured with sufficient inventory to enter COVID-19 clinical trials. The drug addresses underlying causes of ARDS, including loss of endothelial function.